felbamate has been researched along with Body Weight in 6 studies
Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.
felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats on (1) behavioral deficits (employing a battery of assessment tasks days 1-5 post-injury) and (2) blood-brain barrier (BBB) permeability changes (quantifying microvascular alterations according to the extravasation of protein-bound Evans Blue by a spectrophotofluorimetric technique 2 days post-injury)." | 5.34 | NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. ( Angileri, FF; Arcadi, F; Bramanti, P; Caffo, M; Caruso, G; Costa, C; Germanò, A; Hayes, RL; Lewis, SB; Meli, F; Newcomb-Fernandez, J; Pineda, JA; Wang, KK, 2007) |
| "Since 1993, eight new antiepileptic drugs (AEDs) have become available in the United States for the treatment of epilepsy: felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, and zonisamide." | 4.81 | Some common issues in the use of antiepileptic drugs. ( Asconapé, JJ, 2002) |
| " These findings suggest that felbamate dosing should be relatively uncomplicated in children relative to that in adults." | 2.68 | The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. ( Affrime, MB; Banfield, CR; Glue, P; Jen, JF; Jensen, PK; Perhach, JL; Schumaker, RC; Zhu, GR, 1996) |
| "Felbamate is a novel antiepileptic drug currently undergoing clinical trials in the United States." | 2.66 | Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials. ( Fuerst, RH; Graves, NM; Holmes, GB; Leppik, IE; Ludden, TM, 1989) |
| " The aim of this dose-response study was to evaluate the effect of FBM after experimental SAH in rats on (1) behavioral deficits (employing a battery of assessment tasks days 1-5 post-injury) and (2) blood-brain barrier (BBB) permeability changes (quantifying microvascular alterations according to the extravasation of protein-bound Evans Blue by a spectrophotofluorimetric technique 2 days post-injury)." | 1.34 | NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat. ( Angileri, FF; Arcadi, F; Bramanti, P; Caffo, M; Caruso, G; Costa, C; Germanò, A; Hayes, RL; Lewis, SB; Meli, F; Newcomb-Fernandez, J; Pineda, JA; Wang, KK, 2007) |
| "Felbamate is a new antiepileptic drug (AED) with a good safety profile." | 1.29 | Weight loss in patients taking felbamate. ( Bergen, DC; Hoeppner, TJ; Kanner, A; Ristanovic, RK; Waicosky, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asconapé, JJ | 1 |
| Germanò, A | 1 |
| Caffo, M | 1 |
| Angileri, FF | 1 |
| Arcadi, F | 1 |
| Newcomb-Fernandez, J | 1 |
| Caruso, G | 1 |
| Meli, F | 1 |
| Pineda, JA | 1 |
| Lewis, SB | 1 |
| Wang, KK | 1 |
| Bramanti, P | 1 |
| Costa, C | 1 |
| Hayes, RL | 1 |
| Bergen, DC | 1 |
| Ristanovic, RK | 1 |
| Waicosky, K | 1 |
| Kanner, A | 1 |
| Hoeppner, TJ | 1 |
| Banfield, CR | 1 |
| Zhu, GR | 1 |
| Jen, JF | 1 |
| Jensen, PK | 1 |
| Schumaker, RC | 1 |
| Perhach, JL | 1 |
| Affrime, MB | 1 |
| Glue, P | 1 |
| McGee, JH | 1 |
| Butler, WH | 1 |
| Erikson, DJ | 1 |
| Sofia, RD | 1 |
| Graves, NM | 1 |
| Ludden, TM | 1 |
| Holmes, GB | 1 |
| Fuerst, RH | 1 |
| Leppik, IE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial.[NCT03371199] | 21 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for felbamate and Body Weight
| Article | Year |
|---|---|
Some common issues in the use of antiepileptic drugs.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Anticonvulsants; Body Weight; Cognition Disorders; Drug E | 2002 |
2 trials available for felbamate and Body Weight
| Article | Year |
|---|---|
The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling.
Topics: Adolescent; Adult; Aged; Aging; Anticonvulsants; Bayes Theorem; Body Weight; Child; Child, Preschool | 1996 |
Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Clinical Trials as Topic; Double-Blind Method; Felb | 1989 |
3 other studies available for felbamate and Body Weight
| Article | Year |
|---|---|
NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Body Weight; Cerebrovascular Circulation; Dose-Respo | 2007 |
Weight loss in patients taking felbamate.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Child; Epilepsy; Felbamate; Humans; Middle Aged; Ph | 1995 |
Oncogenic studies with felbamate (2-phenyl-1,3-propanediol dicarbamate).
Topics: Adenoma, Liver Cell; Administration, Oral; Animals; Anticonvulsants; Body Weight; Carcinogenicity Te | 1998 |